'Revolutionary' approach to access

Posted 27 September 2024 AM

Chimeric Therapeutics has joined forces with Achieve Clinics, a Los Angeles biotech that connects patients to autologous CAR T-cell therapies they may need in the future.

The collaboration centres around Chimeric's CHM CDH17, the the world's first cadherin 17-directed CAR T-cell therapy currently in Phase 1 clinical trials for advanced gastrointestinal (GI) cancers in the US.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here